Updating results

503 results

Sort: Relevance | Date

Macular oedema (diabetic) - pegaptanib sodium [ID452]

In development [GID-TAG280] Expected publication date: TBC

Technology appraisal guidance In development

Venous thromboembolism - apixaban (acute medical illness) [ID310]

In development [GID-TAG419] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]

In development [GID-TAG417] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (advanced or metastatic) hormone-sensitive - lapatinib [ID115]

In development [GID-TAG404] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small-cell, untreated) - paclitaxel formulated as albumin-bound nanoparticles (with carboplatin) [ID553]

In development [GID-TAG528] Expected publication date: TBC

Technology appraisal guidance In development

Juvenile idiopathic arthritis - abatacept [ID27]

In development [GID-TAG402] Expected publication date: TBC

Technology appraisal guidance In development

Glioblastoma - bevacizumab [ID80]

In development [GID-TAG413] Expected publication date: TBC

Technology appraisal guidance In development

Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) ID622

In development [GID-TAG360] Expected publication date: TBC

Technology appraisal guidance In development

Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]

In development [GID-TAG424] Expected publication date: TBC

Technology appraisal guidance In development

Multiple myeloma - bortezomib (consolidation therapy) [ID529]

In development [GID-TAG320] Expected publication date: TBC

Technology appraisal guidance In development

Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]

In development [GID-TAG435] Expected publication date: TBC

Technology appraisal guidance In development

Generalised anxiety disorder - quetiapine [ID347]

In development [GID-TAG421] Expected publication date: TBC

Technology appraisal guidance In development

Atrial fibrillation - vernakalant [ID454]

In development [GID-TAG428] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line) [ID488]

In development [GID-TAG432] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

In development [GID-TAG403] Expected publication date: TBC

Technology appraisal guidance In development

Obesity - lorcaserin [ID337]

In development [GID-TAG420] Expected publication date: TBC

Technology appraisal guidance In development

Obesity - phentermine (with topiramate) [ID543]

In development [GID-TAG439] Expected publication date: TBC

Technology appraisal guidance In development

Osteoarthritis and rheumatoid arthritis - cox-II inhibitors (review) [ID388]

In development [GID-TAG372] Expected publication date: TBC

Technology appraisal guidance In development

Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]

In development [GID-TAG423] Expected publication date: TBC

Technology appraisal guidance In development

Atherothrombotic events - vorapaxar [ID616]

In development [GID-TAG493] Expected publication date: TBC

Technology appraisal guidance In development

Prostate cancer - intensity modulated radiotherapy [ID17]

In development [GID-TAG396] Expected publication date: TBC

Technology appraisal guidance In development

Colon cancer (adjuvant) - irinotecan [ID379]

In development [GID-TAG380] Expected publication date: TBC

Technology appraisal guidance In development

Head and neck cancer - contusugene ladenovec [ID76]

In development [GID-TAG407] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small cell) - afatinib [ID357]

In development [GID-TAG422] Expected publication date: TBC

Technology appraisal guidance In development

Pancreatic cancer (locally advanced, metastatic) - masitinib [ID566]

In development [GID-TAG330] Expected publication date: TBC

Technology appraisal guidance In development

Prostate cancer (prevention) - dutasteride [ID75]

In development [GID-TAG409] Expected publication date: TBC

Technology appraisal guidance In development

Prostate cancer (hormone refractory) - atrasentan [ID390]

In development [GID-TAG379] Expected publication date: TBC

Technology appraisal guidance In development

Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]

In development [GID-TAG300] Expected publication date: TBC

Technology appraisal guidance In development

Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]

In development [GID-TAG440] Expected publication date: TBC

Technology appraisal guidance In development

Glaucoma - lerdelimumab (CAT-152) [ID383]

In development [GID-TAG381] Expected publication date: TBC

Technology appraisal guidance In development

Eltrombopag for untreated severe aplastic anaemia ID1198

In development [GID-TA10284] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab with epacadostat for untreated malignant melanoma ID1423

In development [GID-TA10330] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer ID1228

In development [GID-TA10203] Expected publication date: TBC

Technology appraisal guidance In development

Bevacizumab as monotherapy or in combination with lomustine for glioblastoma – second line [ID978]

In development [GID-TA10149] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (advanced and/or metastatic) - sunitinib (in combination with capecitabine) [ID319]

In development [GID-TAG410] Expected publication date: TBC

Technology appraisal guidance In development

Clostridium difficile associated diarrhoea - tolevamer [ID378]

In development [GID-TAG389] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small-cell, second line treatment) - vandetanib [ID46]

In development [GID-TAG405] Expected publication date: TBC

Technology appraisal guidance In development

Heart failure (acute decompensated) - nesiritide [ID384]

In development [GID-TAG376] Expected publication date: TBC

Technology appraisal guidance In development

Atrial fibrillation - idraparinux sodium [ID375]

In development [GID-TAG383] Expected publication date: TBC

Technology appraisal guidance In development

Venous thromboembolism (recurrent) - idraparinux sodium [ID395]

In development [GID-TAG384] Expected publication date: TBC

Technology appraisal guidance In development

Psoriatic arthritis (moderate to severe) - leflunomide [ID391]

In development [GID-TAG385] Expected publication date: TBC

Technology appraisal guidance In development

Diabetic retinopathy - ruboxistaurin [ID382]

In development [GID-TAG386] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]

In development [GID-TAG388] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (first line treatment) - sunitinib (in combination with a taxane) [ID58]

In development [GID-TAG391] Expected publication date: TBC

Technology appraisal guidance In development

Juvenile idiopathic arthritis - adalimumab [ID385]

In development [GID-TAG400] Expected publication date: TBC

Technology appraisal guidance In development

Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95]

In development [GID-TAG416] Expected publication date: TBC

Technology appraisal guidance In development

Leukaemia (chronic myeloid) - nilotinib (discontinued) [ID79]

In development [GID-TAG408] Expected publication date: 01 May 2011

Technology appraisal guidance In development

Atrial fibrillation - ximelagatran [ID376]

In development [GID-TAG377] Expected publication date: TBC

Technology appraisal guidance In development

Clinically isolated syndrome - beta interferons and glatiramer acetate [ID109]

In development [GID-TAG415] Expected publication date: TBC

Technology appraisal guidance In development

Bevacizumab for untreated malignant pleural mesothelioma (ID1183)

In development [GID-TA10197] Expected publication date: TBC

Technology appraisal guidance In development